MedPath

Mitoxantrone

Generic Name
Mitoxantrone
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C22H28N4O6
CAS Number
65271-80-9
Unique Ingredient Identifier
BZ114NVM5P
Background

An anthracenedione-derived antineoplastic agent.

Indication

For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
Associated Therapies
Autologous hematopoietic stem cell transplant
Clinical Trials
Related News

Use of Topotecan in Patients With Refractory Acute Leukemia

Phase 2
Completed
Conditions
Non-Hodgkin's Lymphoma
Leukemia
Interventions
Drug: Topotecan
Drug: Mitozantrone
Drug: Etoposide
First Posted Date
2004-12-31
Last Posted Date
2013-09-25
Lead Sponsor
US Department of Veterans Affairs
Target Recruit Count
10
Registration Number
NCT00100477
Locations
🇺🇸

North Florida/South Georgia Veterans Health System, Gainesville, Florida, United States

Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia

Phase 1
Completed
Conditions
Leukemia
Interventions
Drug: etoposide
Drug: mitoxantrone hydrochloride
Drug: valspodar
First Posted Date
2004-04-29
Last Posted Date
2013-02-01
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
3
Registration Number
NCT00002912
Locations
🇺🇸

Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

🇺🇸

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

🇺🇸

Simmons Cancer Center - Dallas, Dallas, Texas, United States

and more 52 locations

Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer

Phase 2
Completed
Conditions
Stage IV Prostate Cancer
Adenocarcinoma of the Prostate
Recurrent Prostate Cancer
Interventions
Drug: ixabepilone
Drug: mitoxantrone hydrochloride
Drug: prednisone
First Posted Date
2003-04-09
Last Posted Date
2017-02-23
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
80
Registration Number
NCT00058084
Locations
🇺🇸

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 3
Completed
Conditions
Prostate Cancer
Interventions
Drug: docetaxel
Drug: mitoxantrone
Drug: estramustine
Drug: prednisone
First Posted Date
2003-01-27
Last Posted Date
2014-02-25
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
770
Registration Number
NCT00004001
Locations
🇺🇸

CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States

🇺🇸

Mayo Clinic, Jacksonville, Florida, United States

🇺🇸

CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States

and more 13 locations

Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia

Phase 1
Completed
Conditions
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Untreated Adult Acute Lymphoblastic Leukemia
Untreated Adult Acute Myeloid Leukemia
Interventions
Drug: cytarabine
Drug: mitoxantrone hydrochloride
Drug: alvocidib
Other: pharmacological study
Other: laboratory procedure
First Posted Date
2003-01-27
Last Posted Date
2013-10-08
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
53
Registration Number
NCT00016016
Locations
🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy